Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why on earth would you want to read that ...
`We won’t be limited by the balance sheet` Davis Merck CEO
yesterday ...
From FT
'Last week investors saw the first glimpse of Davis’s strategy when Merck agreed to pay $11.5bn for Acceleron Pharma, a biotech company that develops protein-based therapies to treat a rare blood pressure disorder and some cancers. Davis said the deal would help to diversify Merck’s portfolio and that he was scouring for other targets to help the company contend with the looming patent cliff.
“I’m confident we have the firepower, the capability, the focus and urgency to do that,” Davis told the Financial Times. “This is the first step on a journey to continue to build out our pipeline so that we have the ability to grow sustainably well into the next decade?.?.?.?We won’t be limited by the balance sheet.”
Yep, an absolute scoop like this for any journal comes at a price...
As Flip pointed out they can publish every day of the week if they like .
there`s no more `hold the front page ` to contend with .
From FT
'Last week investors saw the first glimpse of Davis’s strategy when Merck agreed to pay $11.5bn for Acceleron Pharma, a biotech company that develops protein-based therapies to treat a rare blood pressure disorder and some cancers. Davis said the deal would help to diversify Merck’s portfolio and that he was scouring for other targets to help the company contend with the looming patent cliff.
“I’m confident we have the firepower, the capability, the focus and urgency to do that,” Davis told the Financial Times. “This is the first step on a journey to continue to build out our pipeline so that we have the ability to grow sustainably well into the next decade?.?.?.?We won’t be limited by the balance sheet.”
Merck on deals hunt as patent cliff looms for top cancer drug
(Financial Times) -- Merck’s cancer immunotherapy Keytruda is a wonder drug that has transformed not just the survival odds of thousands of patients but also the pharmaceutical company’s fortunes. However, with the drug poised to lose patent...
The full story is available on Bloomberg to Financial Times corporate subscribers. Click here for more.
Click here to see the story as it appeared on the Financial Times web site. Registration is required.
Recommended Stories
Danish Dude , did you see all the shite that AP writer and Ae Kuster crappy You tube video were peddling re it takes 500 years to get published bla bla bla...
Name one of the publications that had the PH3 TLD results of a 14 year 3 continent cancer trial ... NONE
It will be published when LP wants it published , that will have been the deal for them to get the scoop ..
Duffy joined NWBio in good faith, worked with LP for a handful of months then got away from her as quickly as he could ...
That`s what happened, nothing to do with the science all to do with her being a nightmare to work with ...
Thanks Woj & DD
Tbh no idea , only real tangible forward looking legally binding thing they`ve said in along time is :
`NO RAISE TILL AFTER TLD `
can you tell me which post of Gus you`re referring to please Woj ?
Swiss .... not a chance ...
I was sure another multi billion spend for Merck must be off the table due to balance sheet , but Davis literally answered my concern.
So about turn for me ....its Merck or BMY ...
From FT
'Last week investors saw the first glimpse of Davis’s strategy when Merck agreed to pay $11.5bn for Acceleron Pharma, a biotech company that develops protein-based therapies to treat a rare blood pressure disorder and some cancers. Davis said the deal would help to diversify Merck’s portfolio and that he was scouring for other targets to help the company contend with the looming patent cliff.
“I’m confident we have the firepower, the capability, the focus and urgency to do that,” Davis told the Financial Times. “This is the first step on a journey to continue to build out our pipeline so that we have the ability to grow sustainably well into the next decade?.?.?.?We won’t be limited by the balance sheet.”
Merck on deals hunt as patent cliff looms for top cancer drug
(Financial Times) -- Merck’s cancer immunotherapy Keytruda is a wonder drug that has transformed not just the survival odds of thousands of patients but also the pharmaceutical company’s fortunes. However, with the drug poised to lose patent...
The full story is available on Bloomberg to Financial Times corporate subscribers. Click here for more.
Click here to see the story as it appeared on the Financial Times web site. Registration is required.
Recommended Stories
skitahoe ...
..wtf are you talking about :
TLD RELEASE WILL BE VIA A JOURNAL
how many freakin times....
Flip , the mighty Capital group cut 11m (50%) of their shares over the last period and i reckon they are on their
way out totally .
They are the reason NVCR shares went up in the first place .
I know the Capital Group well without going in to detail ..
Thanks Rudy
Not a chance ....
One year anniversary has already passed ...
...do you really think they PR'd the day they locked ..not a chance
I`d suggest we are 13 if not even 14 months since the actual DL ..
That’ll do ….
Thanks but a PH3 TLD release of a 14 year trial would surely be
a coup for their main publication…
…the Lancet publishes WEEKLY
Maverick , why 1st November ?
The Lancet is a weekly online publication , there’s no more ‘hold the front page’ or restrictions
on number of articles etc , so why 1st November ?
Norm Macdonald has died. …What a shame
Many hysterical clips on You Tube for any comedy fans
There`s not a single chance in hell Merck in the running after this weeks acquisition.
Personally I completely believe LP has the put and the call , and quite frankly if she delivers the end points well and truly met I wont give a feck ..
..looks like revisits of current certified sites is ultra quick in any case .. check todays update ...
TBH Kab, even if this one has been misinterpreted the substance of what I`ve said still stands.
`Weird / Strange` ...indeed it would be if this was an isolated example of lack of transparency and accountability... but its not , and the list of things that would appear under examples of Linda Powers` lack of transparency and accountability is truly staggering.
I kind of choose to deal with it by saying she must have the goods to be able to carry on business in this fashion , but she sure gives ammunition to all and sundry by behaving like its a private company.
The last documented public commitment of significant note she made was `no more funding till post data release `
That was a material forward looking statement on which I bought shares, and I imagine many others either did or at the very least it materially impacted their decision making process.
If she raises prior to TLD , I will sue the same day, and the ridiculous thing is a part of me would love it .
`are` / `were`.... bit confusing but I get your question ..
(... and do I detect a subtle Julius Caesar reference with the end justifying the means ...)
I`m not saying he`s not doing his bit towards the success of the trial,
I`m saying he`s is exceptionally prone to talking utter shite.
..so when Billy Liar says we'll be attacked... just remember the loon knows no rules..
`Suspicion always haunts the guilty mind.`
William Shakespeare
King Henry VI, Part III
ACT V SCENE VI London. The Tower.( which is where id love to put LG ... )
Jack the good news is Les talks utter unadulterated shite 24/*7 to anyone that'll listen.
...Ask yourself do you have have any examples of Les predicting something that did actually happen, and if the answer is yes how close was his time line prediction compared to when it actually occurred.
In a court of law he would ne labelled ` Unreliable `
..anyone remember (amongst many other figments of his imagination)
RAMO / Overstock / T Zero / `interim results in a major journal in weeks `( ..JTM.. months and months later) and soooooo much more
....and to think some of these things were in NDA's that I signed .... beyond belief ..
..As I said it aint gonna be Merck ... so one suitor down one left to go ..
Merck Slims Keytruda Reliance With Pricey Acceleron M&A: React
Contributing Analysts Michael Shah (Pharma)
RECENT EVENT REACTION: Though Merck's acquisition of Acceleron commands a 12.5X EV-to-2025 sales multiple, topping recent deals in the sector, it hands Merck sotatercept, which has an attractive mechanism and blockbuster sales potential, helping to reduce Keytruda reliance from 2024. As well as a likely high margin, the pulmonary arterial hypertension (PAH) drug could reinvigorate Merck's small cardiovascular portfolio. This includes Adempas, which is also for PAH, and as such could fuel antitrust questions. A rival bid can't be ruled out.
Spot on ...
Before you watch the video be prepared for this :
* he says as at 25/9/19 30 trials never registered the results within a year and 67% of them averaged 260 days late .
* he says of 4768 55% violated the 12 month rule
* he says 99% of trials fail .
See where I`m going ..... utter shite
Before you watch the video be prepared for this :
* he says as at 25/9/19 30 trials never registered the results within a year and 67% of them averaged 260 days late .
* he says of 4768 55% violated the 12 month rule
* he says 99% of trials fail .
See where I`m going ..... utter shite
...he`s probably right when he says we do not get news in
the short term and yes could easily trade sub $1....
I remember it like it was yesterday , listening to LP casually announce the compassionate arm `the sickest of the sick` and oh yes the first outing of the phrase ` coming months ` ...
What ?? ...if I thought that I would have said it .
Anders, Kabanushi...
The headline line says a lot .. and this was 100% a Northwest placed piece FYI
https://www.businessweekly.co.uk/news/biomedtech/northwest-biotherapeutics-creating-300-cambridge-uk-jobs